Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Halozyme Therapeutics is a biopharma company that licenses its proprietary ENHANZE drug delivery technology to major pharmaceutical partners including Roche, Bristol Myers Squibb, Janssen, and AbbVie. The platform enables subcutaneous administration of biologics that would otherwise require intravenous infusion, generating high-margin royalty revenue from partner product sales. The company also develops its own oncology pipeline while benefiting from a capital-light royalty model with 83.6% gross margins.
Halozyme licenses its recombinant human hyaluronidase enzyme (rHuPH20) technology to pharmaceutical partners who incorporate it into their biologic drugs to enable faster subcutaneous delivery. The company receives upfront payments ($20-125M per target), development milestones, regulatory milestones, and mid-to-high single-digit royalties on net sales of commercialized products. This asset-light model requires minimal manufacturing capex as partners handle production, creating exceptional operating leverage. Pricing power stems from the technology's clinical differentiation (reducing 30-90 minute IV infusions to 3-5 minute SC injections) and high switching costs once integrated into partner development programs.
Commercial performance of key ENHANZE-enabled partner products, particularly Darzalex Faspro (Janssen) and Phesgo (Roche), which drive quarterly royalty revenue
Announcement of new ENHANZE licensing deals or expansion of existing partnerships into additional targets
Clinical trial readouts and regulatory approvals for partner products incorporating ENHANZE technology
Pipeline progress for proprietary oncology assets and potential business development transactions
Royalty rate disclosures and revenue guidance updates as partner products transition from launch to peak sales
Partner concentration risk: Revenue heavily dependent on commercial success of a limited number of ENHANZE-enabled products from major partners; underperformance of Darzalex Faspro or Phesgo would materially impact royalty streams
Technology obsolescence: Competing drug delivery platforms (alternative subcutaneous formulation technologies, oral biologics, gene therapies) could reduce demand for ENHANZE licensing
Patent expiration: Core ENHANZE patents begin expiring in the 2030s, potentially enabling biosimilar competition or reducing partnership economics
Regulatory risk: Changes in FDA or EMA approval pathways for combination products or subcutaneous formulations could delay partner product launches
Alternative subcutaneous delivery technologies from competitors like Argenx (FcRn technology) or novel formulation approaches that don't require enzyme co-administration
Partner internalization: Large pharmaceutical companies developing proprietary subcutaneous delivery capabilities to avoid royalty payments on future products
Pricing pressure: Healthcare cost containment initiatives could reduce partner product pricing, directly impacting royalty revenue calculated on net sales
Elevated debt/equity ratio of 3.00 creates refinancing risk if credit markets tighten, though strong cash flow provides coverage
Negative net income growth (-28.6% YoY) despite revenue growth suggests margin compression or increased expenses that warrant monitoring
Dependence on continued partnership deal flow to sustain growth; any slowdown in new licensing agreements would pressure forward revenue projections
low - Biopharmaceutical royalty revenue is largely insulated from economic cycles as partner products treat serious conditions (cancer, autoimmune diseases) with inelastic demand. Healthcare spending remains stable through recessions, and partner companies (Roche, J&J, BMS) have diversified global revenue bases. However, severe economic downturns could delay new partnership signings or reduce R&D budgets at smaller biotech partners.
Rising interest rates create modest headwinds through two channels: (1) higher discount rates compress valuation multiples for high-growth biotech stocks, particularly affecting the 7.6x P/S multiple, and (2) increased financing costs for smaller biotech partners could slow new deal activity. However, the company's strong cash generation ($0.7B operating cash flow) and minimal capex requirements reduce direct financing risk. The 3.00 debt/equity ratio suggests some refinancing exposure, though high margins provide debt service coverage.
Minimal direct credit exposure as the business model does not involve lending or significant receivables risk. Partner creditworthiness is high (investment-grade pharmaceutical companies), reducing royalty payment risk. Broader credit market tightening could indirectly impact M&A valuations for potential acquisitions or partnership deal structures, but core operations remain insulated from credit cycles.
growth - The 37.6% revenue growth, asset-light royalty model, and exposure to high-growth oncology/immunology markets attract growth investors seeking leverage to biopharmaceutical innovation without traditional drug development binary risk. The 39% one-year return and strong momentum (14.1% three-month return) appeal to growth-at-reasonable-price investors given the 11.9x EV/EBITDA multiple. Limited dividend yield focuses investor base on capital appreciation rather than income.
moderate-to-high - Biotech stocks typically exhibit elevated volatility (sector beta ~1.2-1.4), driven by binary clinical/regulatory events for partner products, quarterly royalty revenue variability, and sensitivity to interest rate changes affecting growth stock valuations. The 141.6% ROE and high leverage (3.00 D/E) amplify returns but also increase downside risk. Partnership-dependent revenue model creates event-driven volatility around deal announcements and partner earnings reports.
